<DOC>
	<DOCNO>NCT00193388</DOCNO>
	<brief_summary>In phase II trial , evaluate weekly schedule topotecan second-line treatment patient small cell lung cancer</brief_summary>
	<brief_title>Weekly Topotecan Second-Line Treatment Small Cell Lung Cancer</brief_title>
	<detailed_description>Upon determination eligibility , patient receive : - Topotecan</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>To include study , must meet following criterion : Small Cell Lung cancer Progression one previous regimen Measurable evaluable disease Able perform activity daily live assistance Adequate bone marrow , liver kidney function No three previous course radiation therapy Accessible treatment follow Must give write informed consent prior study entry You participate study follow apply : Central nervous system involvement Serious active infection Serious underlie medical condition Other active neoplasm Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>